Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Ramon Andrade De Mello


Honorary Senior Clinical Researcher

  • Consultant Medical Oncologist
  • Professor of Medical Oncology


Professor Ramon Andrade De Mello is a Senior Consultant Medical Oncologist/Professor in Oxford University Hospitals NHS Foundation Trust with experience in the screening, diagnosis and treatment of cancer patients, especially breast and gastrointestinal cancers. Since 2020, he has been permanent professor of the Postgraduate Programme in Medicine at Universidade Nove de Julho (UNINOVE), São Paulo, Brazil, developing translational research in the area of biomarkers in oncology and pharmacoeconomics. He is leader of the discipline of medical oncology at UNINOVE, where he can exchange experience and contribute to the training of several postgraduate students, in addition to being an effective member of the ethics committee of this university.

He graduated in Medicine from the Federal University of Ceará, in Fortaleza, Brazil. He completed the CCT equivalent training in Medical Oncology at the Instituto Português de Oncologia do Porto, Portugal, where he had the opportunity to acquire solid experience in different types of malignant tumours, in addition to experience in autologous and heterologous transplantation.

He has clinical skills in prescribing and handling oncological therapies (chemotherapy, immunotherapy and targeted therapies) and clinical management of cancer patients and their complications. He completed a PhD in Oncology at the University of Porto, Portugal, and a ESMO supported Clinical Fellowship Visit at the Royal Marsden Hospital, London, UK, where he learned the principles of translational research and had the opportunity to increase his experience in more than 40 clinical trials sponsored by the pharmaceutical industry. He has more than 200 scientific publications in indexed journals, conference proceedings, chapters and books, as well as participating in the editorial board of several international reputed scientific journals, where he consolidates a vast academic experience.

In addition, Prof. De Mello is the Director of the Precision Oncology and Health Economics Research Group with more than 12 national/international members in a core structure with the Post-Graduation Program of Medicine, Nine of July University (UNINOVE), São Paulo, Brazil. The aforementioned implementation is one of the Prof. De Mello biggest legacy where he stills coordinates research grants applications, financial sources management, laboratory operational processes, PhD and Master thesis students, junior medical students’ fellows, manuscript writing, conference presentations, professional coaching in a nice corporative and organizational environmental.


Zhu JH, De Mello RA, Yan QL, Wang JW, Chen Y, Ye QH, Wang ZJ, Tang HJ, Huang T. (2020) MiR-139-5p/SLC7A11 inhibits the proliferation, invasion and metastasis of pancreatic carcinoma via PI3K/Akt signaling pathway, Biochim Biophys Acta Mol Basis Dis., 1;1866(6):165747,  PMID: 32109492

De Mello RA, Lordick F, Muro K, Janjigian YY (2019) Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies, Am Soc Clin Oncol Educ Book, 39:237-247, PMID: 3109964

Roque K, Ruiz R, Otoya-Fernandez I, Galarreta J, Vidaurre T, de Mello RA, Neciosup S, Mas L, Gómez H. (2022) The impact of telemedicine on cancer care: real-world experience from a Peruvian institute during the COVID-19 pandemic, Future Oncol., 18(31):3501-3508, PMID: 36367446

Xie K, Feng J, Fan D, Wang S, Luo J, Ren Z, Zheng C, Diao Y, De Mello RA, Tavolari S, Brandi G, Roden AC, Ren B, Shen Y, Xu L. (2022) BARX2/FOXA1/HK2 axis promotes lung adenocarcinoma progression and energy metabolism reprogramming. Transl Lung Cancer Res., 11(7):1405-1419, PMID: 35958341

de Mello RA, Amaral GA, Neves NM, Lippo EG, Parini F, Xu S, Tolia M, Charalampakis N, Tadokoro H, Castelo-Branco P, Zhu J. (2021) Current and potential biomarkers in gastric cancer: a critical review of the literature, Future Oncol., 17(25):3383-3396, PMID: 34291647